Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis

Table 2

The univariate and multivariate analyses in the ICIs cohort: HR for PFS and OS.

Variable	PFS				OS
	Univariate		Multivariate		Univariate		Multivariate
	HR (95% CI)	value	HR (95% CI)	value	HR (95% CI)	value	HR (95% CI)	value
Age (year)
<65	1				1
≥65	0.95 (0.62–1.47)	0.822			0.82 (0.41–1.66)	0.590
Smoking status
Nonsmoker	1				1
Smoker	0.88 (0.54–1.41)	0.586			1.07 (0.48–2.37)	1.070
Metastatic sites number
<2	1		1		1		1
≥2	1.76 (1.11–2.78)	0.016	1.43 (0.88–2.33)	0.144	2.23 (1.11–4.75)	0.024	2.44 (1.08–5.54)	0.033
ICIs-drug
Sintilimab	1				1
Nivolumab	0.94 (0.46–1.90)	0.857			0.55 (0.18–1.64)	0.282
Pembrolizumab	0.93 (0.49–1.74)	0.926			0.73(0.31–1.72)	0.468
ICIs treatment modality
Monotherapy	1				1
Combination therapy	0.91 (0.58–1.43)	0.669			0.71 (0.35–1.45)	0.351
ICIs line
1	1				1
≥2	1.59 (0.98–2.60)	0.061			1.92 (0.87–4.27)	0.108
Histology
Nonsquamous	1				1		1
Squamous	1.36 (0.89–2.09)	0.152			2.70 (1.32–5.52)	0.006	4.22 (1.97–9.04)	<0.001
Stage
I–IIIA	1				1
IIIB–IV	1.24 (0.60–2.57)	0.567			2.33 (0.56–9.75)	0.246
RDW (%)
<16	1				1
≥16	1.53 (0.85–2.77)	0.157			1.12 (0.39–3.18)	0.834
LDH (IU/L)
<250	1				1
≥250	2.32 (1.22–4.40)	0.010			2.23 (0.80–6.21)	0.124
ALB (g/L)
≥35	1		1		1		1
<35	1.54 (1.49–4.34)	0.001	2.32 (1.34–4.00)	0.003	4.48 (2.12–9.47)	<0.001	3.90 (1.77–8.64)	0.001
dNLR
≤3	1		1		1		1
>3	1.92 (1.17–3.15)	0.010	1.71 (1.03–2.85)	0.037	2.16 (1.02–4.54)	0.044	1.70 (0.78–3.70)	0.18
PLR
≥160	1				1
<160	0.88 (0.58–1.35)	0.561			0.51 (0.25–1.04)	0.065

RDW, red blood cell distribution width; PLR, platelet-to-lymphocyte ratio.